Clinical Trials Program

Changing Many Lives, One Trial at a Time

At Sidra Medicine, we are entrusted with the care of Qatar’s most precious resource – its children.

Our Clinical Trials Program offers a new lease of hope to young patients with rare and complex diseases. It focuses on clinical trials that will benefit children in the Arab region, particularly those with rare diseases that lack effective treatment.

The program embodies our commitment towards advancing pediatric healthcare and pioneering treatment protocols and therapies for the benefit of the people in Qatar and the region.

Our clinical services in partnership with our Research division, has identified a number of critical areas in pediatric health related to rare and genetic diseases to expand treatment options and redefining what is possible in pediatric medicine.

A historical lack of research particularly within the Arab population has led to a significant data gap, limiting the development of effective and personalized treatments for pediatric rare diseases. In fact, many current treatment options have shown reduced effectiveness in Middle Eastern, African and Persian populations because they have not been designed with these genetics in mind.

The Clinical Trial Program at Sidra Medicine will focus on representing Middle Eastern pediatric populations from the very beginning of the drug testing process.  It will play a crucial role in building a robust database of knowledge that will enable more effective and personalized treatment approaches tailored to the unique needs of the population.

Frequently Asked Questions

 

Current clinical trials at Sidra Medicine

 

Sidra Medicine has been selected as a site for several pharma sponsored industry clinical trials to date, which are at various stages of feasibility assessment.

 

Trials currently active:

Condition/Disease: Congenital Hyperinsulinism (CHI)

 

RZ358-301 (SunRIZE):
The purpose of the trial is to evaluate the efficacy and safety of RZ358 - an investigational product for the treatment of Congenital Hyperinsulinism (CHI) as add-on to standard-of-care (SOC) therapy compared to SOC alone.

 

The trial is currently being done in coordination with Sidra Medicine’s Endocrinology Outpatient and Inpatient wards and the Outpatient Infusion Centre (OPIC).
Age group: ≥3 months-<18 years of age

 

Contact us

 

If you would like to speak to us about enrolling your child in a Clinical Trials Program, please email clinicaltrialsoffice@sidra.org